Novo Nordisk (NVO-NYSE, $56.75). Victoza use Reduces Risk of Heart Attacks & Strokes

Those taking Victoza reported a statistically significant reduction in heart attack and stroke occurrence, in the largest study of its kind to date.

The test seems to clearly demonstrate superiority for Victoza over competing products produced by Merck and Sanofi. Importantly, questions posed in the conference call seemed to suggest that the cardiovascular benefits may also be replicated in an oral formulation, presently under development by Novo Nordisk.

Posted in Open Blog

Leave a Reply

Recent Comments